ReviewCancers2022
Novel Cellular Therapies for Hepatocellular Carcinoma.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Contrast-enhanced ultrasound and clinical features for preoperative prediction of GPC-3 expression in hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials.World journal of gastroenterology · 2026Review
- Article
- Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies.Theranostics · 2025Review
- Research trends of cellular immunotherapy for primary liver cancer: A bibliometric analysis.Human vaccines & immunotherapeutics · 2024Article
- In silico and cheminformatics prediction with experimental validation of an adipogenesis cocktail, sorafenib with rosiglitazone for HCC dedifferentiation.Journal, genetic engineering & biotechnology · 2024Article
- Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future.Journal of clinical and translational hepatology · 2024Review
- Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2024Article
- Diversified applications of hepatocellular carcinoma medications: molecular-targeted, immunotherapeutic, and combined approaches.Frontiers in pharmacology · 2024Review
- Hepatocellular Carcinoma With Tumor Thrombus Extension Into the Right Atrium of the Heart.Cureus · 2023Article
- Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial.Hepatology international · 2023Article
- Recent advances in recurrent hepatocellular carcinoma therapy.World journal of hepatology · 2023Review
- Evolving therapeutic landscape of advanced hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2023Review
- Immunotherapy, targeted therapy, and their cross talks in hepatocellular carcinoma.Frontiers in immunology · 2023Review
- Evolution by innovation as a driving force to improve TCR-T therapies.Frontiers in oncology · 2023Review
- Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.International journal of molecular sciences · 2022Review
- Exploring Hepatocellular Carcinoma Mortality Using Weighted Regression Estimation for the Cohort Effect in Taiwan from 1976 to 2015.International journal of environmental research and public health · 2022Article
- Editorial: Targeting Thyroid Hormone-Dependent Pathways in Proliferative and Degenerative Disorders.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Most patients present with advanced disease, and current gold-standard management using tyrosine kinase inhibitors or immune checkpoint inhibitors (ICIs) offers modest clinical benefit. Cellular immune therapies targeting HCC are currently being tested in the laboratory and in clinical trials. Here, we review the landscape of cellular immunotherapy for HCC, defining antigenic targets, outlining the range of cell therapy products being applied in HCC (such as CAR-T and TCR-T), and exploring how advanced engineering solutions may further enhance this therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.